Should endotoxin be a research priority in Gram-negative sepsis and septic shock?

Figures & data

Table 1. Characteristics of Studies.

Study	Reference	Year	Time span	Abdominal sepsis	Source control
EUPHAS I	[7]	2009	Dec 2004 – Dec 2007	100%	100%
EUPHAS II	[8]	2016	Jan 2010 – Dec 2014	44%	not clearly reported

Figure 1. A simplified illustration of the relationship between endotoxin and immune host cells. adapted from Marshall JC [3].

MD2: myeloid differentiation factor-2; TLR4: Toll-like receptor 4; MyD88: myeloid differentiation factor 88; IRAK: interleukin receptor-associated kinase; TRAF2: tumor necrosis factor receptor-associated factor 2; NFκB: nuclear factor κB; MAP: mitogen-activated protein; IL-1: interleukin 1; TNF: tumor necrosis factor; PAF: platelet-activating factor.

Cruz DN, Antonelli M, Fumagalli R, et al. Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. Jama. 2009;301:2445–2452.

 PubMed Web of Science ®Google Scholar

Cutuli SL, Artigas A, Fumagalli R, et al. Polymyxin-B hemoperfusion in septic patients: analysis of a multicenter registry. Ann Intensive Care. 2016;6:77.

 PubMed Web of Science ®Google Scholar

Marshall JC. Endotoxin in the pathogenesis of sepsis. Contrib Nephrol. 2010;167:1–13.

 PubMed Web of Science ®Google Scholar